Last updated on February 2020

Low-dose Glucocorticoid Vasculitis Induction Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Microscopic Polyangiitis | Wegener's Granulomatosis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Provision of written informed consent by a patient or a surrogate decision maker
  2. Age=>20 years
  3. New clinical diagnosis of ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis or renal limited ANCA-associated vasculitis) consistent with the 2012 Chapel Hill consensus definitions
  4. Positive test by ELISA for proteinase 3-ANCA or myeloperoxidase-ANCA

Exclusion Criteria:

  1. Prior treatment for ANCA-associated vasculitis before trial entry
  2. ANCA-associated vasculitis related glomerulonephritis (eGFR<15ml/min) or alveolar hemorrhage (oxygen inhalation >2L/min)
  3. Presence of another multisystem autoimmune disease
  4. Known infection with HIV; a past or current history of hepatitis B virus or hepatitis C virus infection
  5. Desire to bear children, pregnancy or lactating
  6. History of malignancy within the past 5 years or any evidence of persistent malignancy
  7. Ongoing or recent (last 1 year) evidence of active tuberculosis
  8. Severe allergy or anaphylaxis to monoclonal antibody therapy
  9. Any concomitant condition anticipated to likely require oral systemic glucocorticoids, immunosuppressants, biologics, plasma exchange or IVIg
  10. Any biological B cell depleting agent (such as rituximab or belimumab) within the past 6 months
  11. Other conditions, in the investigator's opinion, inappropriate for the trial entry

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.